<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20150825073400Z</creation_date><modification_date>D:20150828084800Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-13-846_h_a_dec_4.pdf</pdf_file></head><body><section><header>en en</header><p>european commission
 bruxelles, 28.8.2015c(2015)6119 (final) corr</p></section><section><header>commission implementing decisionof 28.8.2015
 correcting decision c(2015)4366 (final) amending the marketing authorisation granted 
 by decision c(2013)4019(final) for “xtandi - enzalutamide”, a medicinal product for 
 human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission implementing decisionof 28.8.2015
 correcting decision c(2015)4366 (final) amending the marketing authorisation granted 
 by decision c(2013)4019(final) for “xtandi - enzalutamide”, a medicinal product for 
 human use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1,having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof,
 having regard to the changes to the terms of the decision granting the marketing authorisation 
 requested by astellas pharma europe b.v. in accordance with regulation (ec) no 
 1234/2008,
 having regard to the opinions of the european medicines agency, formulated on 23 april 
 2015 and on 21 may 2015 by the committee for medicinal products for human use,
 whereas:
 (1)
 the marketing authorisation granted by decision c(2013)4019(final) for “xtandi- 
 enzalutamide”, a medicinal product for human use has been amended by decision 
 c(2015)3677 and by decision c(2015)4366.
 (2)
 the commission has been made aware that changes introduced in annexes i and iiib 
 of the decision c(2015)3677 were not in annexes i and iiib of decision 
 c(2015)4366. this decision rectifies therefore decision c(2015)4366 (final) by 
 correcting accordingly annexes i and iiib. consequently, it should apply retroactively 
 from the date of notification of that decision.
 (3)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 1oj l 136, 30.4.2004, p. 1.2oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision:article 1decision c(2015)4366 (final) is corrected as follows:annexes i and iiib shall be replaced by the text set out in annexes i and iiib to this decision.
 article 2this decision applies from 24 june 2015. article 3this decision is addressed to astellas pharma europe b.v., sylviusweg 62, nl-2333 be leiden, nederland.
 done at brussels, 28.8.2015
 for the commissionladislav miko
 acting director-general</p></section></body></xml>